Related Experiment Video
Updated: Jul 6, 2025
Strategies for Study of Neuroprotection from Cold-preconditioning
Published on: September 2, 2010
Chicago sky blue 6B exerts neuroprotective and anti-inflammatory effects on focal cerebral ischemia
B Pomierny1, W Krzyżanowska1, A Skórkowska1
1Laboratory for Stroke Research, Department of Toxicological Biochemistry, Jagiellonian University Medical College, Poland.
Insights
Chicago Sky Blue 6B (CSB6B) demonstrated significant anti-inflammatory effects in a rat model of brain ischemia. Posttreatment with CSB6B reduced brain infarct volume and neurological deficits by lowering proinflammatory cytokines.
Area of Science:
- Neuroscience
- Pharmacology
- Inflammation Research
Background:
- Brain ischemia, a major cause of death and disability, triggers glutamate overload and neuroinflammation.
- Glial cell activation releases proinflammatory cytokines, worsening neuroinflammation and immune cell infiltration.
Purpose of the Study:
- To investigate the anti-inflammatory potential of Chicago Sky Blue 6B (CSB6B) in a rat model of focal cerebral ischemia.
- To evaluate CSB6B's effects on neurological deficits, infarct volume, and inflammatory markers.
Main Methods:
- A 90-minute middle cerebral artery occlusion model was used in rats.
- CSB6B was administered either 2 hours before ischemia (pretreatment) or 1.5 hours after reperfusion (posttreatment).
- Ischemic preconditioning served as a comparator for CSB6B pretreatment.
Main Results:
- Posttreatment with CSB6B significantly reduced neurological deficits and infarct volume.
- CSB6B administration decreased levels of proinflammatory cytokines (Il1β, Il6, Il18, TNFα) in brain tissues.
- CSB6B treatment limited microglia/astrocyte activation and immune cell infiltration.
Conclusions:
- CSB6B exhibits profound anti-inflammatory effects when administered post-ischemia.
- CSB6B shows promise as a pharmacological agent for treating brain ischemia.
- Further research is needed to enhance the drug-like properties of CSB6B for clinical application.
Abstract:
Brain ischemia is one of the leading causes of death and long-term disability worldwide. Cessation of the blood supply to the brain directly stimulates many pathological events, including glutamate overload and neuroinflammation. Glial cell activation occurs shortly after ischemia onset, resulting in the release of proinflammatory cytokines and exacerbation of the detrimental effects of neuroinflammation. Proinflammatory signals influence the infiltration of a wide range of immune cells, including neutrophils, T cells and monocytes/macrophages. In this study, we aimed to verify the potential anti-inflammatory effect of Chicago Sky Blue 6B (CSB6B) in a rat model of focal cerebral ischemia (90-minute middle cerebral artery occlusion). CSB6B was administered 2 h before (pretreatment) or 1.5 h after reperfusion onset (posttreatment). A model of ischemic preconditioning was used as the comparator to pretreatment with CSB6B. The results of indicated that posttreatment with CSB6B had profound anti-inflammatory effects that were associated with reduced neurological deficits and a decreased infarct volume. At 24 h, 3 days and 7 days after brain ischemia, CSB6B administration reduced the protein levels of proinflammatory cytokines, such as Il1β, Il6, Il18 and TNFα, in the cerebral cortex and the dorsal striatum. Treatment with CSB6B also limited the scope of microglia and astrocyte activation and the infiltration of immune cells. Taken together, this study shows that compounds such as CSB6B might be promising pharmacological tools; however, further studies on the improvements in the drug-like properties of these compounds must be undertaken.
